









# 会议手册

Conference manual











#### Organizations:

Hainan Medical University (HNMU), Hainan Academy of Medical Sciences International Center for Aging and Cancer (ICAC)
Samuel Waxman Cancer Research Foundation (SWCRF)
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine The First Affiliated Hospital of Hainan Medical University
The Second Affiliated Hospital of Hainan Medical University

December 13th-14th, 2024

Haikou-China





# 海南医科大学第一附属医院

## (第一临床医学院)简介

海南医科大学第一附属医院始建于1973年,前身为海南医学专科学校附属医院,1993年更名为海南医学院附属医院,2016年更名为海南医学院第一附属医院,2024年更名为海南医科大学第一附属医院,是集医疗、教学、科研、预防、保健、紧急救援于一体的三级甲等综合库院

医院现有两个院区(龙华院区、江东新院区),同时规划建设国兴院区。龙华院区位于海口市中心,占地面积59亩,编制床位1500张。江东新院区位于江东新区,毗邻海南医科大学新校址,占地254.5亩,编制床位2000张,目前大楼已经全部封顶,将于2025年3月竣工,新院区按"第五代"医院标准建设,为海南自由贸易港建设重点项目,届时将更好满足人民群众医疗卫生服务需求。





全院职工2891人,其中硕博占比26.22%,高级职称占比22.07%,博士生导师32人,硕士生导师100人,国家百千万人才2人,国家卫健委有突出贡献中青年专家2人,国务院特殊津贴专家9人,海南省有突出贡献的优秀专家11人,"南海名家"10人,"515人才工程"17人,海南省"千人专项"2人,海南省卫健委"好医生"13人,海南自由贸易港B类人才1人,C类人才18人,D类人才53人,E类人才561人,柔性引进专家26人(其中中国工程院院士1人),双聘专家11人。

医院现有国家临床重点专科和国家临床重点专科建设科室7个(急诊医学科、肿瘤科、神经内科、脊柱外科、呼吸内科、胃肠外科和胸外科)、国家中医药管理局中医药重点学科1个(中医肝胆病学)、国家中医药管理局重点专科1个(针灸科)、省级重点学科4个、省教育厅省级扶持学科2个、省级重点专科19个、省级临床医学研究中心2个。2021年获批建设9个海南省级器官系统疾病中心和临床医学中心,涵盖12个专业;2022年获批4个海南省数字疗法临床试验中心。2022年12月22日,医院挂牌互联网医院;2023年2月15日,获评中西医协同"旗舰"医院试点项目建设单位。

作为海南省首家医学院校附属医院,也是海南省重要医教研基地。医院现有国家国际联合研究中心1个(中-缅区域性重大疾病防治联合研究中心),国家临床医学研究中心分中心1个(国家恶性肿瘤临床医学研究中心分中心),教育部重点实验室(培育)1个("生殖健康及相关

疾病研究与转化"教育部重点实验室),海南省基因检测技术应用示范 中心1个(海南省基因检测技术应用示范中心),院士工作站1个(付小 兵院士工作站),院士团队创新中心1个(陈子江院士团队创新中心),博 士后科研工作站1个,省级重点实验室2个(海南省人类生殖与遗传重点 实验室、海南省创伤与灾难救援研究重点实验室),省级工程研究中心3 个(海南省创新药物临床评价工程研究中心、海南省重大疾病生物样本 资源工程研究中心、海南省热带药物创新与转化工程研究中心),省级 临床医学研究中心2个(海南省地方病(地中海贫血)临床医学研究中心、 海南省代谢性疾病临床医学研究中心),省级人类精子库1个(海南省人 类精子库),生物样本库3个(海南省生物样本库、海南省人类遗传资源 库、教育部重点实验室(急救与创伤研究)人类遗传资源生物样本)。 2011年至2020年, 医院连续10年获批国家自然科学基金项目数量居全 省医疗机构之首;2022年,获批国家自然科学基金项目20项,立项数创 海南省医疗机构历史新高;2023年,获批国家自然科学基金项目18项, 获批数量继续居全省医疗机构首位,其中包括国家杰出青年科学基金 项目1项,是海南省医疗机构获批的首个国家杰青项目。

海南医科大学第一临床医学院作为海南医科大学教学体量最大的临床学院,是临床医学硕士、博士培养单位,也是国家级的临床医学检验住培骨干师资培训基地、中华医学会临床药学分会临床药师师资培训中心和临床教学培训示范中心,具有完善的院校教育、毕业后教育和继续教育教学体系,有国家级专业综合改革项目3项。学院设有临床医学、精神医学、麻醉学、康复治疗学和应用心理学5个专业。其中,临床医学专业为教育部高等学校特色专业建设点、国家一流专业建设点。拥有国家级一流本科课程1门,省级精品课程4门,省级精品在线开放课程5门,省级一流课程7门;具有国家级住院医师规范化培训专业基地21个,国家级重点住院医师规范化培训专业基地2个(全科医学科、急诊科),国家级试点专科医师规范化培训基地2个(普通外科、新生儿围产期医学科)。

由医院负责具体建设和管理的国家紧急医学救援队(海南)于2019年1月通过国家卫健委正式验收,多次为国家重大会议及国内外重大突发公共卫生事件救援任务提供服务保障,曾受到国家卫健委、海南省卫健委的表彰。国家紧急医学救援基地(海南)建设项目为国家首批21个紧急医学救援基地之一,该项目基地位于医院江东院区,占地面积约56亩,于2023年4月12日通过省发改委批复可行性研究报告;5月5日,通过省发改委批复初步设计和概算,项目概算总投资为70953万元;5月30日,正式开工奠基,建设工期3年,截止2024年10月30日,项目累计完成总工程量的48%。

一直以来,医院始终对标公立医院高质量发展要求,稳步推进医教研协同发展,曾获全国卫生健康系统新冠肺炎疫情防控工作先进集体、全国改善医疗服务创新医院、全国妇幼卫生工作先进单位、爱婴医院、全国城市医院思想政治工作先进集体、海南省五佳医院、全省环境优美十佳医院等荣誉称号。坚持改革创新,致力建设热带特色鲜明的国际化高水平医科大学附属医院,努力实现"海南人民大病不出岛"的目标,为健康海南、健康中国建设贡献力量!



# 海南医科大学第二附属医院

## (第二临床医学院)简介

海南医科大学第二附属医院(简称"海医二院")始建于1952年,是一所集医疗、教学、科研、康复及预防保健为一体的大型综合性三级甲等医院。

医院由主院区、东湖分院和乌石分院一院三址组成,占地面积644.7亩,主院区环境优美,树木葱郁,门诊和住院大厅宽敞整洁。医院编制床位2500张,现有职工3117名,拥有552名副高及以上专业技术职称人员、1101名中级职称人员,1110名初级职称人员,其中博硕士研究生559人、本科生1876人。国务院特殊津贴专家3人、国家新世纪百千万人才工程1人、国家卫生部有突出贡献的中青年专家1人、海南省"515"人才工程8人、省优专家3人、高层次人才:B类1人、C类6人、D类63人、E类368人。医院移植医学研究团队、心血管病外科治疗医学研究团队获批海南省"双百"人才团队。

医院以"一部、两所、四院、四中心"发展战略,深入推进学科群打造,目前拥有5个国家级重点专科(心血管外科、胃肠外科、重症医学科、消化内科、心血管内科),3个国家级医学分中心(国家感染性疾病临床研究中心分中心、



The Second Affiliated
Hospital of Hainan
Medical University

国家热带病研究中心海南分中心和国家心血管疾病临床医学研究中心分中心),10个省级重点学科(感染性疾病科、器官移植科、消化内科、普通外科、肝胆外科、心血管内科、心脏大血管外科、热带病科、重症医学科和麻醉科),2个省级医学中心(海南省危重孕产妇救治中心、海南省危重新生儿救治中心),3个省级临床医学研究中心(海南省急危重症临床医学研究中心、海南省热带疾病临床医学研究中心、海南省泌尿系统疾病临床医学研究中心),1个国家卫健委重点实验室(国家卫生健康委员会热带病防治重点实验室),2个研究所(移植医学研究所、肾脏病研究所),2个院士创新平台(于金明院士团队创新中心、樊代明院士团队创新中心),1个院士工作站(马骏院士工作站)。医院拥有全球领先的磁共振引导直线加速器一台、PET/MR一台、3.0T/1.5T磁共振五台、超高端256排宝石CT、320排宽体探测器CT及双源CT等共十一台CT、双板悬吊DSA及单板DSA共三台,ECMO四台、高端心脏、四维超声等大型高新尖端医疗设备,医院目前有设备7909台(套),设备总值11.45亿,100万以上设备180台(套),50万以上设备355台(套);医院医疗特色鲜明,五大实体器官移植及其联合移植、心脏大血管疾病综合救治、急危重症抢救、神经系统疾病综合治疗、肿瘤高端诊断与治疗、热带病与耐多药结核病诊断与治疗、外科快速康复治疗以及突发公共卫生事件处置能力等方面均已达到海南省内领先、国内先进水平。

医院承担海南医学院本科生、硕士研究生、博士研究生、留学生等各个层次人才培养工作;是国家首批住院 医师规范化培训基地,国家全科医师规范化培训基地。

医院党委全面加强党建工作,坚持以党建引领文化,以文化促进发展,全面落实党委把方向、管大局、做决策、保落实,统筹推进医院各项事业健康发展。

海医二院人以执着的医志、高尚的医德、精湛的医术和严谨的学风书写了辉煌的历史。今天的海医二院人正在海南自贸港建设的新征程中,倡导"明德 致知 齐心 济众"的核心理念,秉承"仁善 博学 务实 拓新"的医院精神,践行"竭诚关怀 温情呵护"的服务理念,紧紧围绕"创建国内知名并享誉东南亚的教学研究型医院"的愿景,不忘初心,砥砺前行。













健康前哨®

# 居家抗衰老检测

# 解决方案供应商

# 居家抗衰老检测:

载脂蛋白E4(APOE4)检测试剂盒

专门针对衰老疾病之一阿尔茨海默症的快检产品

NAD指标检测、AKG指标检测、牛磺酸检测

衰老指标持续性居家监测系列服务

# 居家防癌检测:

丙型肝炎病毒IgG抗体检测试剂盒、尿液样本HPV病毒染 色试剂、幽门螺杆菌染色液、大便隐血检测试剂盒.....

个人居家健康检测试剂盒

# 居家送检检测:


肠道菌群检测、HPV检测+TCT细胞联合检测、 幽门呼气试验、感染三项检测、HPV检测


个人健康检测管理系列服务

# 郑州方欣生物 ——您的健康哨兵



扫码了解更多







做自己的健康哨兵。

抗哀更进一步!



# 国药器械 (海南) 有限公司

China Medical Device (Hainan) Co., Ltd. 国药器械成员企业

关爱生命 呵护健康

#### 高度专业化的医疗器械、科研设备全产业链综合服务平台

19 覆盖海南全省 100+

100+

100%

#### 主体业务

医疗产品

八 科研产品

**心** 流通服务

〇 院内管理服务

#### 协同业务



医工服务



多采商城





学术推广

### 让更多的民众享受更好的健康服务

公司始终秉承"关爱生命 呵护健康"的理念,肩负"让更多的民众享受更好的健康服务"的使 命,以"成为具有行业竞争力和国际影响力的最受尊敬医疗器械企业"为愿景,竭诚为广大用户服 务,携手海南自贸港,共创高质量发展新篇章。



# **CONTENTS** 目录

参会须知	01
会议简介	03
会议日程	05
大会主席	10
主讲嘉宾 ······	11
温馨提示	29
会务组通讯录 ······	30
特别鸣谢 ·····	31
会议记录预留页	32









The 6<sup>th</sup> International Conference on Aging and Cancer:
Targeting Common Drivers of Cancer and Aging



- (一)请您仔细阅读本手册,及时了解会议期间活动安排。
- (二)请遵守会议作息时间,按会议日程提前10分钟入场,活动期间将移动电话和其他电子设备设置为静音状态。
- (三)根据安保要求,会议期间请全程佩戴参会证件,凭参会证件出入活动场所;在指定餐厅用餐时请出示餐券。
- (四)请您妥善保管随身行李及贵重物品。
- (五)会议期间会务组将竭诚为您服务,通讯录详见本册尾页。

#### 一、会议模式

本次会议采用"线上线下,同步直播"的形式,线下会议共有300个席位。

### 二、入校流程

- 方案一:1.点开活动前会务组给您发送的参会提醒短信,点击短信中的二维码链接,生成个人专属二维码。 2.出示您的参会专属二维码给学校保卫处工作人员。
- 方案二:关注"掌上海医"公众号→服务大厅→访客预约→访客预约申请→入校预约。
  - \*受访人信息填写:李锦佳 校验受访人姓名
  - \*入校时间填写:12月13日 08:00
  - \*结束时间填写:12月14日 18:00
  - \*来访类型填写:业务拜访
  - \*来访事由填写:参加第六届衰老与肿瘤国际学术会议
  - 审批通过后,请向学校保卫处出示通行证。

#### 三、会议签到

- 1.点开活动前会务组给您发送的参会提醒短信,点击短信中的二维码链接,生成个人专属二维码。
- 2.出示您的专属二维码,在签到处的微光盒子上扫码验证签到。
- 3.工作人员在后台查看签到数据,确认签到完成后发参会证件、领取会议资料。
- 4.会前未进行线上报名的则需现场进行报名、签到。


























# 四、用餐信息

日期	时间	地点	备注
12月13日	12:00-13:30	海南医科大学国际教育大楼榴源餐厅3楼	凭餐券证
12月14日	12:00-13:30	海南医科大学国际教育大楼榴源餐厅3楼	凭餐券证

特别提醒:1、会议期间请到指定地点用餐,用餐凭证为会议餐券,13日、14日报到时在签到处领取。 2、用餐时间如有变动,请以最新通知信息为准。

### 五、会场平面图



### 六、直播回放

扫描下方二维码观看直播回放,有效期至2025年12月14日。







直播回放二维码











The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



由衰老与肿瘤国际研究中心(ICAC)主办的第六届衰老与肿瘤国际学术会议将于2024年12月13日至14日在 海口召开。

The 6th International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging will take place in Haikou, China, on 13-14 December 2024.

衰老是肿瘤的最大风险因素,90%的肿瘤发生在50岁以上人群,患者的年龄影响肿瘤从发生、到转移、再到治疗反应的各个方面。今年的衰老与肿瘤国际学术会议将聚焦于衰老与肿瘤的共同驱动机制,旨在推动针对老龄化人群肿瘤预防和治疗的创新性策略的研发。本次会议将邀请衰老与肿瘤研究领域具有重要影响的国内外知名专家进行大会报告,报告以"线下会议+线上直播"的方式同步进行。

Aging represents the major risk factor for cancer, 90% of cancers occur in people overthe age of 50, and the age of the patient influences every aspect of cancer pathogenesis, from premalignant growths to metastasis, to responses to therapy. This year's International Conference on Aging and Cancer will focus on identifying the shared biological mechanisms underlying both aging and cancer, with the goal of developing innovative strategies for cancer prevention and treatment specifically tailored to aging populations. This conference will invite internationally renowned experts with important influence in the field of aging and cancer research to speak in the form of "online & in person".

#### 衰老与肿瘤国际研究中心介绍

**About the International Center for Aging and Cancer (ICAC)** 

ICAC是由海南医科大学(海南省医学科学院)、上海交通大学医学院附属瑞金医院以及美国塞缪尔·魏克斯曼 癌症研究基金会(SWCRF)共建的科研机构,中心使命是致力于通过创新性基础研究、转化研究及临床研究增进对 衰老和肿瘤的认知,以应对日益严重的全球老龄化问题和与衰老密切相关的肿瘤高发带来的全球健康挑战。

























ICAC was jointly established by the Hainan Medical University, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and the Samuel Waxman Cancer Research Foundation (SWCRF) in 2020. ICAC's mission is to advance the understanding of aging and cancer through innovative laboratory, translational, and clinical research in response to the growing problem of global aging and the high incidence of aging-related cancers. ICAC holds an international conference on aging and cancer annually, bringing together experts from around the world to discuss cutting-edge issues in the field of aging and cancer.

以热带公园、海滩、红树林和火山闻名的海口,12月气候宜人,我们诚挚邀请您相约海口进行学术交流,共享一场学术盛宴,为推动健康中国战略贡献力量。

The weather in December is beautiful in Haikou, which is famous for its tropical parks, beaches, mangrove forests and volcanoes. We warmly welcome you to meet in Haikou for academic exchanges and enjoy a grand banquet of academics.













#### Friday, December 13, 2024

08:30-08:40 (BJS)	OPENING SESSION HOST: SAMUEL WAXMAN & RUIBAO REN	
08:30-08:35 (BJS)	Welcome Remarks by representative of Hainan Medical University	
08:35-08:40 (BJS) (EST, 12/12/2024, 19:35-19:40)	Opening Remarks by Prof. Samuel Waxman, the Founder and CEO of SWCRF TITLE: Aging is the provocateur of the Global Rising Incidence of Cancer	
08:40-12:00 (BJS)	MORNING SESSION HOST: SAMUEL WAXMAN & RUIBAO REN	
08:40-09:10 (BJS)	James L. Kirkland (in person) Cedars-Sinai Medical Center. TITLE: Cancer, Aging, and Cellular Senescence: Potential Roles For Senolytic Interventions	
09:10-09:35 (BJS) (EST, 12/12/2024, 20:10-20:35)	Kornelia Polyak (online) Dana Farber Cancer Institute, Harvard Medical School. TITLE: Midkine as a driver of age-related changes and increase in mammary tumorigenesis	
09:35-10:00 (BJS)	Weiguo Zou (in person) Hainan Medical University, Hainan Academy of Medical Sciences. TITLE: Prx1+ mesenchymal stromal cell senescence drives skeletal senescence and dysregulation of body homeostasis	
10:00-10:25 (BJS)	Raul Mostoslavsky (in person) Massachusetts General Hospital Cancer Center, Harvard Medical School. TITLE: Linking metabolism and epigenetics in aging and cancer: lessons from SIRT6	
10:25-10:40 (BJS)	COFFEE BREAK	
10:40-11:05 (BJS)	Hongkui Deng (in person) Peking University School of Life Sciences. TITLE: TBA	























### Friday, December 13, 2024

16:25-18:00 (BJS)	POSTER SESSION
16:10-16:25 (BJS)	COFFEE BREAK
15:45-16:10 (BJS)	Pengxu Qian (in person) Zhejiang University School of Medicine. TITLE: 造血干细胞衰老的代谢调控
15:20-15:45 (BJS)	Jianwei Wang (in person) Hematology Hospital, Chinese Academy of Medical Sciences. TITLE: Deciphering DNA damage code in aged hematopoietic stem cells
14:55-15:20 (BJS)	Jingxuan Pan (in person) Zhongshan Ophthalmic Center, Sun Yat-sen University. TITLE: Essential role of helicase DDX3X in cancer stem cells
14:30-14:55 (BJS)	Valery Krizhanovsky (in person) Weizmann Institute of Science. TITLE: Cellular senescence on the crossroads of cancer and aging.
14:05-14:30 (CEST,13/12/2024, 7:05-7:30)	Valter Longo (online) The USC Leonard Davis School of Gerontology TITLE: TBA
14:00-15:45 (BJS)	AFTERNOON SESSION HOST: WENSHU WU & SANDRA MCALLISTER
12:00-13:30 (BJS)	LUNCH TIME
11:30-11:55 (BJS)	Sandra McAllister (in person) Harvard Medical School. TITLE: Understanding Immune Aging to Improve Breast Cancer Outcomes
11:05-11:30 (BJS)	Wenshu Wu (in person) International Center for Aging and Cancer, Hainan Medical University. TITLE: The Slug/Snail2 signaling pathways in aging and rejuvenation of muscle stem cells











#### Saturday, December 14, 2024

08:30-08:35 (BJS)	OPENING SESSION HOST: JAMES DEGREGORI & DAOHONG ZHOU	
08:30-08:35 (BJS)	Opening Remarks by Prof. James DeGregori, University of Colorado Anschutz Medical Campus School of Medicine.	
08:35-11:50 (BJS)	MORNING SESSION HOST: JAMES DEGREGORI & DAOHONG ZHOU	
08:35-09:05 (BJS)	Junying Yuan (in person) The Interdisciplinary Research Center of Biology and Chemistry. TITLE: RIPK1 and Aging	
9:05-9:30 (BJS) (EST,13/12/2024, 20:05-20:30)	Rafael de Cabo (online) National Institute of Aging. TITLE: TBA	
09:30-09:55 (BJS)	Zhixiong Xiao (in person) Center of Growth, Metabolism and Aging, Sichuan University. TITLE: Targeting stress-induced senescence to rejuvenate aged organs for healthy aging	
9:55-10:20 (BJS) (CST,13/12/2024, 19:55-20:20)	Darren J. Baker (online) Mayo Clinic. TITLE: Senescent cells promote a permissive tumor microenvironment	
10:20-10:35(BJS)	COFFEE BREAK	
10:35-11:00 (BJS) (CST,13/12/2024, 20:35-21:00)	Daohong Zhou (online) The University of Texas Health Science Center at San Antonio. TITLE: Using PROTAC to Develop Safer and Better BCL-XL/2 Targeting Senolytics for NAFLD/NASH/HCC	
Yuanyuan Lu (online) Xijing Hospital, Fourth Military Medical University. TITLE: Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells		

























#### Saturday, December 14, 2024

11:25-11:55 (BJS)	ORAL PRESENTATION	
11:25-11:35 (BJS)	Bo Jiao Ruijin Hospital, Shanghai Jiao Tong University School of Medicine ABSTRACT: Loss of Golga7 suppresses oncogenic Nras-driven leukemogenesis without detectable toxicity in adult mice	
11:35-11:45 (BJS)	Huo Fengjiao Tongji University Abstract: Disruption of the Circadian Rhythm Is Exacerbated by Aging and Ameliorated by Time-restricted Feeding	
11:45-11:55 (BJS)	朱顺沧 福建医科大学省立临床医学院, 福建省立医院 Abstract: cCCT2 Induces Senescence in Pancreatic Cancer Cells Following Chemotherapy and Promotes Immune-Mediated Senescence Clearance	
12:00-13:30 (BJS)	LUNCH TIME	
14:30-18:00 (BJS)	POSTGRADUATE FORUM	
1 <del>1</del> .50-16.00 (DJS)	POSTGRADUATE FORUM	
14:30-14:40 (BJS)	POSTGRADUATE FORUM  Yuankang Feng Second Hospital Affiliated to Tianjin Medical University ABSTRACT: 过氧化物酶体基因PEX10通过降低ROS来抑制前列腺癌细胞的衰老	
	Yuankang Feng Second Hospital Affiliated to Tianjin Medical University	











#### Saturday, December 14, 2024

15:00-15:10 (BJS)	Hui Guo Wenzhou Medical University ABSTRACT: Adenosine A2A receptor deficiency alleviates retina aging in aged mice
15:10-15:20 (BJS)	Yuping Yang Zhuzhou Central Hospital, Xiangya Hospital of Central South University ABSTRACT: An Oncolytic Virus-like particle for Targeted gene Therapy of melanoma
15:20-15:30 (BJS)	Yingying Lin Ruijin Hospital, Shanghai Jiao Tong University School of Medicine ABSTRACT: Targeting PGE2 mediated senescent neuron improves tumour therapy
15:30-16:30 (BJS)	CERTIFICATES  ICAC and <i>Aging and Cancer</i> will issue certificates to authors of the best abstracts and posters.





























### Samuel Waxman

- $\cdot$  Distinguished Service Professor of Medicine, Mount Sinai School of Medicine;
- · Honorary Professor and Co-Director of the Center of Differentiation Therapy at Shanghai Jiao Tong Medical University;
- · Founder and CEO of the Samuel Waxman Cancer Research Foundation (SWCRF).



# James DeGregori

- · Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research;
- · Dpt. of Biochemistry and Molecular Genetics;
- · University of Colorado Anschutz Medical Campus; School of Medicine.



## Ruibao Ren

- · Director of International Center for Aging and Cancer;
- · Former Director Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine;
- · K.C. Wong Chair Professor of Shanghai Jiao Tong University;
- · Principal Investigator in Hainan Medical University;
- · Associate Editor of Journal of Hematology & Oncology;
- · Associate Editor of Aging AND Cancer.









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



# 主讲嘉宾



James L. Kirkland Professor in Cellular Senescence and Senolytics, Cedars-Sinai Medical Center

TITLE: Cancer, Aging, and Cellular Senescence: Potential Roles **For Senolytic Interventions** 

Biography: James L. Kirkland, M.D., Ph.D., is Director of the Center for Advanced Gerotherapeutics at Cedars-Sinai Medical Center, Los Angeles and Emeritus Professor of Medicine at Mayo Clinic, Rochester, Minnesota. Dr. Kirkland's research is on the contribution of aging processes, particularly cellular senescence, to multiple disorders and diseases across the lifespan and development of gerotherapeutics: agents and strategies for targeting these aging mechanisms to delay, prevent, alleviate, or treat the conditions that cause the bulk of disability, mortality, and health expenditures across the developed and developing world. Dr. Kirkland discovered senolytic drugs, agents that selectively eliminate senescent cells. Dr. Kirkland and then others demonstrated that senolytic agents enhance healthspan and treat multiple diseases in animal models, human cells, and tissue explants. He published the first composite biomarker gerodiagnostic score of senescent cell burden that is sensitive to drug interventions in humans and the first clinical trials of senolytic drugs. He is preparing or conducting clinical studies of senolytics, including for infections, frailty, Alzheimer's disease, diabetes/obesity, osteoporosis, cancer survivors, idiopathic pulmonary fibrosis, pre-eclampsia, glioblastoma, complications of space travel, agricultural applications, restoring function of organs from old donors to enable their use for transplantation, and others. He has more than 325 publications (H index: 110) and holds 24 patents. Dr. Kirkland is Principal Investigator of the National Institutes of Health Translational Geroscience Network (R33 AG061456), which brings together academic institutions across the US to translate healthspan interventions, including senolytics and other drugs that target fundamental aging processes, from bench to bedside, and is currently involved in over 85 interventional and observational clinical trials. He is President-Elect of the Healthy Longevity Medicine Society, immediate past President of the American Federation for Aging Research, a past member of the National Advisory Council on Aging of the National Institutes of Health, past chair of the Biological Sciences Section of the Gerontological Society of America, and past member of the Clinical Trials Advisory Panel of the National Institute on Aging. He is a board-certified specialist in internal medicine, geriatrics, and endocrinology and metabolism. Dr. Kirkland is the 2020 recipient of the Irving S. Wright Award of Distinction from the American Federation for Aging Research



























袁钧瑛 院士、主任 中国科学院上海有机化学研究所生物与化学交叉研究中心

题目:RIPK1 and Aging

简介:袁钧瑛,分子生物学家,中国科学院外籍院士,美国艺术与科学院院士、美国国家科学院院士,哈佛大学 医学院细胞生物学系终身教授,中国科学院生物与化学交叉研究中心主任。袁钧瑛教授的主要研究目标是揭 示哺乳动物细胞中调控细胞死亡的分子机制。袁钧瑛教授开创两个主要的细胞死亡研究领域,包括细胞凋亡 (apoptosis)和细胞坏死(necroptosis),做出了里程碑式的贡献。她的工作阐明了一系列在这两种细胞死 亡方式中的关键驱动分子,分子机制以及与人类疾病的关系。

在20世纪90年代,袁钧瑛教授首先发现了半胱天冬酶(caspases)作为物种间高度保守的驱动细胞凋亡的关 键分子,并阐明了Bcl-2和caspase在介导细胞凋亡中的关系。随后,袁钧瑛教授发表了一系列细胞凋亡领域 的经典论文,包括发现caspase-11 调控caspase-1的激活在炎症和凋亡中的关键驱动作用,和caspase-8 对BID的切割在诱导线粒体损伤在细胞凋亡中的作用。袁钧瑛教授的另一个重要学术贡献是首先发现了哺乳 动物细胞坏死的可调控性。她的工作定义了程序性细胞坏死(necroptosis),一种哺乳动物细胞中可调控的 细胞坏死方式,并阐明了RIPK1是介导necroptosis的关键分子。这个发现打破了学术界中坏死是被动不受 调控的传统观念,揭示了细胞坏死的分子机理和靶向RIPK1作为临床治疗手段的新方向。已有大量研究表明 RIPK1活化介导细胞炎症和细胞坏死、参与了多种人类重大炎症疾病和神经退行性疾病的病理发生和发展、 包括老年痴呆症,多重硬化症,脊髓侧索硬化症,以及关节炎和肠炎。另外,袁教授还发现了一种抑制细胞死 亡并同时促进细胞恢复稳态的小分子,阐明了小分子的作用靶标和分子机制,为治疗神经退行性疾病提供了 新的干预策略。









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



Weiguo Zou Investigator of Molecular Cell Science, Hainan Medical University, Hainan Academy of Medical Sciences

TITLE: *Prx*1+ mesenchymal stromal cell senescence drives skeletal senescence and dysregulation of body homeostasis

Biography: Dr. Weiguo Zou is a vice-chancellor, professor in Hainan Medical University. He was awarded the National Science Foundation for Distinguished Young Scholars of China in 2017. Dr. Zou has undertaken projects under the National Program on Key Basic Research Project (973), Major Program and Key Program of the National Natural Science Foundation of China, and the Strategic Priority Research Program of CAS.Dr. Zou's research interests include mesenchymal stem cells and functional stem cells of the locomotor system, the molecular and genetic mechanisms that govern bone development and remodeling and related skeletal diseases. He has revealed important role of protein ubiquitination modifications (Nat Cell Biol. 2011, Mol Cell. 2022, Cell Res. 2016, Nat Commun. 2017) and epigenetic regulations (Sci Adv. 2020a, Bone Res. 2018&2021, Cell Death Differ. 2023) in bone development and remodeling, and discovered several key molecules affecting RUNX2 activity (J Clin Invest. 2011, J Exp Med. 2013, Nat Commun. 2016&2022; Sci Adv. 2020b). He also demonstrated that the mechanical sensing protein PIEZO1 regulated bone homeostasis via osteoblastosteoclast crosstalk (Nat Commun. 2020). In recent years, Dr. Zou's group has identified new stem/progenitor cells including Itm2a+ periosteal skeletal stem cells (J Clin Invest. 2024), Pdgfra+Osx- fibrous periosteum cells (Dev Cell. 2024), Ctsk+ tendon progenitors (J Clin Invest. 2020), Ctsk+ periosteal progenitors (J Clin Invest. 2019), and Uts2r+ postnatal nucleus pulposus progenitors (Adv Sci., 2022 Cover Story).



























**邓宏魁** 教授、主任 北京大学生命科学学院

题目: TBA

简介:邓宏魁, 2024年未来科学大奖"生命科学奖"获得者, 北京大学博雅讲席教授、昌平实验室领衔科学家、长江学者特聘教授、北京大学干细胞研究中心主任, 清华-北大生命科学联合中心高级研究员, 国家杰出青年科学基金获得者, 973项目和国家重点研发计划首席科学家。课题组长期以来致力于开发调控细胞命运的新方法和建立多潜能干细胞制备的全新底层技术, 累计发表论文160余篇, 被引用16,000余次, 尤其在小分子化合物诱导细胞命运转变方面做出了一系列开拓性工作:1)首次实现完全使用小分子化合物逆转"发育时钟", 让小鼠体细胞重新获得多潜能性(Science, 2013), 在后续的研究工作中揭示了化学重编程全新的分子机制(Cell, 2015; Cell Stem Cell, 2018), 一系列成果开创了全新的体细胞重编程体系; 2)首次实现完全使用小分子化合物诱导人类体细胞转变为多潜能干细胞(hCiPS细胞)(Nature, 2022), 是我国从源头上独创的新一代多潜能干细胞制备技术; 3)利用小分子化合物建立了一种全新的具有全能性特征的干细胞(EPS细胞)(Cell, 2017), 从小鼠2细胞胚胎建立了新型全能性干细胞(TPS细胞)(Cell Res, 2022); 4)利用小分子化合物实现功能成熟细胞在体外的长期维持(Science, 2019), 从多潜能干细胞诱导制备功能成熟的肝细胞, 在急性肝衰猪模型上成功完成了人工肝治疗的动物实验; 从多潜能干细胞高效分化制备功能成熟的胰岛细胞, 在糖尿病小鼠和猴模型上验证了有效性和安全性(Nature Medicine, 2022); 5)实现小分子化合物诱导小鼠体细胞成为功能性神经元(Cell Stem Cell, 2015), 并实现了在成年小鼠大脑中将体细胞原位转变神经元的体内重编程(Cell Discov, 2021)。













肖智雄

Director, Center of Growth, Metabolism and Aging, Dean of Academic Affairs, College of Life Sciences, Sichuan University

TITLE: Targeting stress-induced senescence to rejuvenate aged organs for healthy aging

简介: 肖智雄, 四川大学生命科学学院学术院长, 四川大学"生长代谢衰老研究中心"主任.中组部首批国家高层次人才专家, 中国侨联特聘专家。科技部重大科学研究计划973项目首席科学家。国家基金委重点项目负责人、国际合作重点项目负责人。主要从事肿瘤发生发展、肿瘤代谢和衰老研究, 在Nature、Cancer Cell、PNAS、Molecular Cell、Nature Communications、Oncogene、Redox Biology, PLOS Biology等国际一流杂志上发表论100余篇。现为Cell Death and Disease 编委。STTT (Signal Transduction and Targeted Therapy)副主编。

**Biography:** Dr. Zhi-Xiong Jim Xiao, Director, Center of Growth, Metabolism and Aging, Dean of Academic Affairs, College of Life Sciences; Sichuan University. Chief Scientist, 973 research program of Ministry of Science and Technology of China. Principal Investigator, Key Projects of NSFC. Research in Xiao lab focuses on cancer metastasis, metabolism and aging. Dr. Xiao is an editor of Cell Death and Disease and an Associate editor of STTT (Signal Transduction and Targeted Therapy)..

























**吴文书** 教授 海南医科大学衰老与肿瘤国际研究中心

题目:The Slug/Snail2 signaling pathways in aging and rejuvenation of muscle stem cells

简介:吴文书,博士:毕业于华东师范大学,上海交通大学医学院硕士毕业,德克萨斯州立大学M.D.安德森癌症中心博士毕业,曾在哈佛大学医学院Dana-Farber癌症研究所从事博士后研究,历任哈佛大学医学院讲师,缅因健康研究所/Tufts大学医学院助理教授,加州大学旧金山分校Benioff儿童医院研究员(PI),伊利诺伊大学芝加哥分校医学院教授(tenured);2024年全职加入海南医科大学衰老与肿瘤国际研究中心。研究领域涵盖胚胎干细胞、血液干细胞、白血病、肌肉干细胞和衰老等前沿科学课题。作为第一作者或通讯作者在《Cell》、《Blood》、《J Clin Invest.》、《Nature Communications》、《Molecular Cancer》、《Leukemia》、《Molecular Therapy》、《Stem Cell Reports》、《Stem Cell Translational Medicine》、《Cell Research》、《Oncogene》等国际知名学术期刊上发表了一系列研究论文。他的研究首次揭示了辐射对人体造血系统造成损伤的细胞和分子生物学机制,此发现曾被《CELL》杂志选为封面故事。曾主持了多项由美国国立卫生研究院(NIH)等科研机构资助的研究项目,并多次受邀参加NIH的课题评审委员会,以及英国医学研究会(MRC)和以色列科技基金会的课题评审工作;是《Nature Medicine》、《Blood》、《Stem Cell》、《Molecular Therapy》等近十种学术杂志的审稿人,担任《Genes & Diseases》杂志的编委会委员,以及《Frontiers in Molecular and Cellular Pathology》和《Scientific Reports》杂志的审稿编辑。













**潘景轩** 教授、副主任 中山大学,眼病防治全国重点实验室

题目:Essential role of helicase DDX3X in cancer stem cells

简介:潘景轩,中山大学教授,眼病防治全国重点实验室副主任,国家杰出青年基金获得者,教育部"长江学者" 奖励计划入选者,国家重点研发项目首席科学家,兼任中国药理学会肿瘤药理学专业委员会候任主任委员,中国老年学和老年医学学会肿瘤基础及转化研究专委会主任委员,广东省药理学会肿瘤药理学专业委员会主任委员,广东省病理生理学会肿瘤专业委员会主任委员。曾在美国德克萨斯大学MD Anderson Cancer Center工作8年(1998-2006),2006年中山大学"百人计划"引进回国任中山医学院教授、博导,2010年入选国家杰出青年基金获得者。主要从事肿瘤药理学研究,研究兴趣集中在肿瘤靶向药物耐药和肿瘤干细胞干性的调控机制及其药物干预,发现PRMT7、EZH2、NAE1等肿瘤干细胞的新可成药性靶点,发现克服伊马替尼耐药的系列先导化合物,在Cell Metabolism, Science Translational Medicine(入选2021年中国血液学十大研究进展),J Clin Invest, Signal Transduct Target Ther, Cancer Res及 Clin Cancer Res等专业杂志上发表SCI论文91篇,主持承担包括国家自然科学基金重点项目、国家重点研发项目(首席科学家)在内的多项国家级课题。担任《Molecular Cancer》(IF 37.3)副主编。

























Jianwei Wang Principle Investigator of Experimental Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College

TITLE: Deciphering DNA damage code in aged hematopoietic stem cells

Biography: Dr. Jianwei Wang is currently Principle Investigator in State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College. He obtained his bachelor degree in Beijing University of Aeronautics and Astronautics in 2002 and master degree in Peking Union Medical College in 2007 and doctor degree in Ulm University (Germany) in 2012. After finishing postdoc training in Leibniz Institute for Aging Research (Germany), Dr. Wang joined Tsinghua University as an independent principle investigator in School of Pharmaceutical Sciences from the beginning of 2016 and moved to Chinese Academy of Medical Sciences since the beginning of 2024. DNA damage accumulation, characterized byyH2AX, has been considered the driving force of HSC aging. Faithful DNA replication is pivotal for the maintenance of genome stability. Any molecular event interfering with DNA replication, collectively named replication stress, confers DNA vulnerable. A previous study has shown that replication stress is a potent driver of functional decline in old HSCs. While, the critical molecular event leading to replication stress in aged HSCs has not been clearly elucidated. We observed that imbalance of RNA between nuclear and cytoplasm with aging results in DNA damage accumulation.













钱鹏旭 研究员 浙江大学医学院

题目:造血干细胞衰老的代谢调控

简介:钱鹏旭,浙江大学医学院研究员。国家高层次人才项目入选者(2018),国家优青项目入选者(2022), 国家重点研发计划"干细胞及转化研究"青年项目首席科学家(2018),浙江省杰出青年基金获得者(2019)。 现任中国生理学会血液生理学分会委员,中国病理生理学会实验血液学专业委员会委员,中国细胞生物学学 会干细胞专业分会委员,中国细胞生物学学会衰老细胞生物学分会委员,中国生物医学工程学会干细胞工程 技术分会常务委员。主要研究方向为治疗性血细胞的功能调控机制及应用。近年来以通讯或第一(含共同)作 者身份在Nature Cell Biology, Cell Stem Cell, Lancet Haematology, Cell Research, Blood等国际 高水平杂志上共发表SCI论文58篇,总引用次数近3500次。曾获得美国血液学协会青年学者奖、国际干细胞 学会年会旅行奖等个人荣誉。

研究摘要:造血干细胞(HSC)衰老伴随着造血重建功能障碍,包括再生和植入能力的丧失、髓系分化偏倚和 造血恶性肿瘤风险升高。最近有报道称,宿主健康和免疫的关键调节因素肠道微生物群会影响造血。然而, 目前有限的经验证据解释了肠道微生物群对衰老造血的直接影响。在2023年发表在Blood期刊上的一项研 究中, 我们从年轻小鼠向老年小鼠进行粪便微生物群移植(FMT), 观察到老年受体小鼠的淋巴分化显著增加, 髓系分化减少。整合的微生物组和代谢组分析揭示了FMT重塑了肠道微生物群组成和代谢物景观,而与色 氨酸相关的代谢物促进了造血的恢复和老年HSC的恢复。在2024年发表在Nat Aging期刊上的工作, 我们从 200只年轻小鼠和150只老年小鼠中分离出15种造血细胞类型,并利用高通量非靶向代谢组学测序技术鉴定 出了超过2000种代谢物,揭示了不同造血细胞之间的代谢差异,并绘制了年轻和年老小鼠不同造血细胞的特 异性代谢图谱。将体外培养系统和体内干预实验相结合,对潜在代谢物进行了筛选,并最终确认了尿苷作为 一种高效的代谢物、能够显著恢复衰老HSC的多种生物学特性。总之、该项研究强调了代谢物在HSC衰老中 的至关重要性。

























卢瑗瑗 教授、副主任 空军军医大学西京医院消化内科

题目:Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells

简介:卢瑗瑗,空军军医大学西京医院消化内科副主任。消化系肿瘤整合防治全国重点实验室PI。国家自然科 学基金杰青、优青获得者。美国Vanderbilt大学博士后。中国抗癌协会常务理事、青年理事会副理事长。中华 医学会消化病学分会消化道肿瘤协作组副组长。CSCO肠癌专委会委员。Cancer Letters、Cellular Oncology 期刊编委。长期从事消化系肿瘤尤其是胃肠道肿瘤的基础和临床研究, 在靶向治疗和免疫治疗方面积累了较 多经验。以第一/通讯作者在Cell、Nature Medicine、J Clin Invest、Mol Cancer、JITC等期刊发表SCI论 著40余篇, 编撰专著12部, 编撰临床肿瘤指南11部。负责国家自然科学基金6项, 国家十四五重点研发项目课 题负责人, 获陕西省科技进步一等奖、空军高层次科技人才、陕西省三秦学者、肿瘤青年科学家奖。

Biography: Prof. Yuanyuan Lu, Professor & Deputy director, Xijing Hospital of Digestive Diseases. State Key Laboratory of Holistic Integrative Management of GI Cancers. National Clinical Research Center for Digestive Diseases. Fourth Military Medical University, Xi' an, China. GI Oncologist. Recipient of The National Science Fund for Distinguished Young Scholars. Postdoctoral fellow, Vanderbilt University Medical Center, USA. Vice President of Youth Committee, Chinese Anti-Cancer Association. Winner of China Young Oncology Scientist Award. 6 grants from National Natural Science Foundation of China (NSFC). Published more than 40 SCI papers including Cell, Nat Med, JCI etc.









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



Kornelia Polyak Professor of Medicine Dana-Farber Cancer Institute, Harvard Medical School

TITLE: Midkine as a driver of age-related changes and increase in mammary tumorigenesis

Biography: Kornelia Polyak, MD, PhD, is Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a co-leader of the Dana-Farber Harvard Cancer Center Cancer Cell Biology Program. Dr. Polyak is an internationally recognized leader of breast cancer research. Her laboratory is dedicated to the molecular analysis of human breast cancer with the goal to identify differences between normal and cancerous breast tissue, determine their consequences, and use this information to improve the clinical management of breast cancer patients. Main areas of interests are: (1) how to accurately predict breast cancer risk and prevent breast cancer initiation and progression, (2) better understand drivers of tumor evolution with special emphasis on metastatic progression and therapeutic resistance, and (3) novel therapeutic targets in breast cancer with focus on triple-negative and inflammatory breast cancer. Dr. Polyak have received numerous awards including the Paul Marks Prize for Cancer Research, the AACR Outstanding Investigator Award for Breast Cancer Research, and the 14th Rosalind E. Franklin Award for Women in Science. She is a recipient of the NCI Outstanding Investigator award (2015 and 2022) and received a Distinguished Alumna Award from Weil-Cornell in 2020. Dr. Polyak was elected as American Association for the Advancement of Science Fellow in 2019, member of the Fellows of the AACR Academy in 2020, elected to the National Academy of Sciences and the National Academy of Medicine in 2022, and to the American Academy of Arts and Sciences in 2024. She was also a recipient of the American Cancer Society Research Professor Award in 2022, received the 2023 AACR Distinguished Lectureship in Breast Cancer Research award, and in 2024 she was elected to the American Academy of Arts and Sciences.

























The 6<sup>th</sup> International Conference on Aging and Cancer:



Rafael de Cabo

Senior Investigator of Experimental Gerontology Section, National Institute of Aging.

TITLE: TBA

Biography: After receiving his B.S. and M.S. from the University of Cordoba, Spain, Dr. de Cabo earned his Ph.D. in 2000 from the Department of Foods and Nutrition at Purdue University. Upon completing his graduate education, he received a postdoctoral position in the Laboratory of Neurosciences at the National Institute on Aging in Baltimore, Maryland. In 2004, he was appointed as a tenure-track investigator in the Laboratory of Experimental Gerontology. He is now a senior investigator and Chief of the Translational Gerontology Branch at NIA. His research has focused on the effects of nutritional interventions on basic mechanisms of aging and age-related diseases and on improving our understanding of the molecular mechanisms for the effects of caloric restriction on aging and pharmacological Interventions for healthy aging. Ultimately his research aims to identify interventions that will improve healthspan and lifespan with translational potential to benefit human aging. He is the author or co-author of 350 publications on aging including the leading journals in the world including New England Journal of Medicine, Nature, Nature Medicine, Science, Cell, Cell Metabolism, Nature Neuroscience, Nature Reviews Drug Discovery. A search of his works indicates that his papers have been cited over 50,000 times and he has an h index of 112. Dr. de Cabo's honors and awards include the American Federation for Aging Research Irving S. Wright Award of Distinction (2023), the Denham Harman Award (2023) of the American Aging Association, Purdue University Diamond Award, Department of Foods and Nutrition (2016), AFAR's Vince Cristofalo Rising Star Award (2014), Fellow of the Gerontological Society of America (2010), Nathan Shock New Investigator Award of the Gerontological Society of America (2006), Paul E. Glenn Award for Meritorious Research from The American Aging Association. Dr de Cabo is Deputy Editor in Chief, the Journal of Gerontology Biological Sciences and serves on the editorial boards of Aging Cell, BBA-Molecular Mechanisms of Disease, Aging Research Reviews, Longevity & Healthspan, Impact Aging, AGE and is one of the founding editors of Microbial Cell.









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



Raul Mostoslavsky

Professor of Medicine, Scientific Director Massachusetts General Hospital Cancer Center, Harvard Medical School

TITLE: Linking metabolism and epigenetics in aging and cancer: lessons from SIRT6

Biography: Raul Mostoslavsky have been working in the field of chromatin and metabolism for the last seventeen years of his career. During his post-doctoral research, Dr. Mostoslavsky was the first to generate knockout mouse models for all the sirtuins. When he started his own laboratory, having those mice put him in an ideal position to study their molecular functions. Dr. Mostoslavsky is currently in the MGH Cancer Center, one of the leading cancer research centers in the US. His background in chromatin, mammalian systems and molecular biology, and the environment he is currently in, are all critical elements that contributed to his ability to publish high impact research, and will be key in pursuing our ongoing projects. Dr. Mostoslavsky's team work was among the first to identify critical crosstalk between chromatin dynamics and metabolic adaptations (Mostoslavsky et al., Cell 2006; Finkel et al., Nature 2009; Boon et al., Nat. Metab. 2020), particularly through studying the histone deacetylase SIRT6. Among other things, Dr. Mostoslavsky's team work, which has been cited more than 30,000 times, identified SIRT6 as a critical modulator of glucose metabolism (Zhong et al., Cell 2010), functioning as a repressor of transcriptional elongation, influencing cellular fitness, organismal development and cancer (Sebastian et al., Cell 2012; Kugel et al., Cell 2016; Etchegaray et al., Mol. Cell 2018; see full list of publications below). In parallel, Dr. Mostoslavsky's team have identified metabolic adaptations in cancer as highly heterogeneous, something that was not predicted from past work in the field (Choi et al., Nat. Metab. 2021; Sebastian et al., Nat Comm 2022; Linder et al., Nat. Metab. 2023), and are currently expanding these studies in the context of metastatic disease (Ferrer et al., Nat. Cell Bio, 2024). For this particular proposal, our expertise on chromatin regulation will be critical. Beyond Dr. Mostoslavsky's own research, he has served as Scientific Director of the MGH Cancer Center for the past 3 years. In this role, he oversees the research work of ~45 Principal Investigators, providing governance, mentoring, and leadership to a research enterprise that continues to grow and is ranked among the best Cancer Centers in the country.





























**Daohong Zhou** 

Professor with Tenure, Biochemistry and Structural Biology, The University of Texas Health Science Center at San Antonio

TITLE: Using PROTAC to Develop Safer and Better BCL-XL/2 Targeting Senolytics for NAFLD/NASH/HCC

Biography: Dr. Daohong Zhou is a professor in the Department of Biochemistry & Structural Biology and a Joe R. and Terry Lozano Long Distinguished Chair of Developmental Therapeutics at the Long School of Medicine, University of Texas Health San Antonio (UTHSA). Dr. Zhou also serves as the Co-Director of the CPRIT-supported Center of Innovative Drug Discovery (CIDD) and as the Associate Director for Drug Development at the Mays Cancer Center (MCC). Dr. Daohong Zhou has published more than 180 peer reviewed scientific articles and book chapters. His research has led to the discovery of the first potent and broad-spectrum senolytic agent, ABT263 (a dual Bcl-2 and Bcl-xl inhibitor), that can selectively kill senescent cells. This discovery may lead to new therapeutics for various age-related diseases. More recently, he developed several proteolysis targeting chimeras (PROTACs) that can target Bcl-xl and other proteins of interest for degradation. Dr. Zhou's efforts in the development of promising senolytics and cancer therapeutics has led to the FDA approval of DT2216, a Bcl-xl PROTAC, in phase I studies, and the founding of two biotechnology companies, Unity Biotechnology (https://unitybiotechnology.com/) and Dialectic Therapeutics (https://www.dtsciences.com/). Using the PROTAC drug development platform, he is developing additional specific antitumor and better senolytic agents.









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



Sandra S. McAllister

Associate Professor of Medicine
Harvard Medical School
Hematology Division, Brigham & Women's Hospital
TITLE: Understanding Immune Aging to Improved

TITLE: Understanding Immune Aging to Improve Breast Cancer Outcomes

cancer control and response to therapy. Her group conducted the first pre-clinical trial to evaluate CDK4/6 inhibition combined with immune checkpoint blockade (Goel, DeCristo, et al., Nature, 2017). That work formed the rationale for a phase 1b clinical trial, which reported improved objective response rate over standard therapies for breast cancer patients. Based on their work to understand the effects of age on disease progression and response to immunotherapy (Marsh, et al., Cancer Research, 2016; Sceneay, Goreczny, et al., Cancer

Biography: Dr. McAllister's lab group studies the role of aging and immune fitness in breast

Discovery, 2019), she and her colleagues launched 3 clinical studies and formed the Older Women with Breast Cancer Research and Treatment Team. Their team is working toward developing therapies that will benefit the diversity of patients with breast cancer.

Dr. McAllister received her undergraduate degree from the University of Michigan in Ann Arbor and completed her Ph.D. studies in molecular and cellular biology at Washington University School of Medicine in St. Louis. She joined Robert Weinberg's laboratory at the

Whitehead Institute for Biomedical Research as a postdoctoral fellow where she established new pre-clinical models to study breast cancer pathophysiology. She joined the faculty of

Brigham & Women's Hospital and Harvard Medical School in 2009, and is also an affiliate member of the Harvard Stem Cell Institute, an Associate Member of the Broad Institute,

and a Member of the Dana Farber/Harvard Cancer Center. Dr. McAllister is an American

Cancer Society Scholar, a recipient of the AACR Gertrude B. Elion Cancer Research Award, and a DOD Era of Hope Award Scholar. In 2012, President Obama presented her with the

Presidential Early Career Award for Scientists and Engineers, the highest early career honor

bestowed by the U.S. Government.























Darren J. Baker Professor of Biochemistry and Molecular Biology, Mayo Clinic

TITLE: Senescent cells promote a permissive tumor microenvironment

Biography: Darren Baker, PhD, is a Professor of Biochemistry and Molecular Biology and Pediatrics at the Mayo Clinic in Rochester, Minnesota, USA. He received his bachelor's degree from the University of Minnesota in Biology and Chemistry, his master's degree from Mayo Clinic College of Medicine in Tumor Biology and his Ph.D. in Biomedical Sciences at the University of Nijmegen in the Netherlands. His laboratory focuses on the involvement of senescent cells to aging and age-related diseases, with particular focus on neoplastic transformation and neurodegenerative disease. Using novel genetically engineered mouse models that allow for the elimination of senescent cells, he was one of the first to demonstrate that both premature and normal aging are driven by increased incidences of senescence. Furthermore, utilization of this model has been instrumental in demonstrating that lung tumors in mice can be attenuated through removal of these damaging cells. Studies from his lab have been identified as one of the top 10 breakthroughs of the year by Science in both 2011 and 2016. In 2019, he was recognized with the Rising Star Award from the Mahoney Institute for Neurosciences from the University of Pennsylvania for his work in neurodegenerative disease. He is funded by the NIH (NCI and NIA), Cure Alzheimer's Fund, Ellison Medical Foundation, Mayo Clinic Children's Research Center, and the Alzheimer's Disease Research Center of Mayo Clinic. Additionally, he is a co-director of the Glenn Laboratories of Mayo Clinic for Senescence Research sponsored by the Glenn Foundation for Medical Research and the director of the Transgenic and Gene Knockout facility of Mayo Clinic.













Valery Krizhanovsky Professor of Molecular Cell Biology, Weizmann Institute of Science

TITLE: Cellular senescence on the crossroads of cancer and aging

Biography: Valery Krizhanovsky is a Professor in Department of Molecular Cell Biology, Weizmann Institute of Science, Israel. Krizhanovsky laboratory studies the role of senescent cells in diseases, cancer and aging. His lab was among the labs which discovered the role of senescence during embryonic development in mammals, specifically focusing on the placenta. During aging senescent cells accumulate in the organism, and contribute to age-related diseases and aging. They discovered the mechanisms of interaction between NK cells and senescent cells and has shown that elimination of senescent cells by the immune system plays a protective role in diseases and aging and supports tissue fitness. Krizhanovsky lab discovered molecular mechanisms that regulate the viability of senescent cells. Targeting these mechanisms allows pharmacological elimination of senescent cells in vivo. They showed that such elimination of senescent cells from premalignant pancreas limits development of pancreatic cancer. Krizhanovsky lab study how presence of senescent cells is regulated during normal aging and age-related diseases. Manipulations of senescent cells in vivo allow us to understand the mechanisms of interaction of senescent cells with their microenvironment and dissect their role in cancer and aging.



























Valter Longo
Professor in Biological Science.
The USC Leonard Davis School of Gerontology

TITLE: TBA

**Biography:** Valter Longo, PhD, is the Edna Jones Professor in Gerontology and Professor in Biological Science. He is also the Director of the USC Longevity Institute. He is interested in understanding the fundamental mechanisms of aging in yeast, mice and humans by using genetics and biochemistry techniques. He is also interested in identifying the molecular pathways conserved from simple organisms to humans that can be modulated to protect against multiple stresses and treat or prevent cancer, Alzheimer's Disease and other diseases of aging. The focus is on the signal transduction pathways that regulate resistance to oxidative damage in yeast and mice.









The 6<sup>th</sup> International Conference on Aging and Cancer: Targeting Common Drivers of Cancer and Aging



# 温馨提示

#### 一、天气信息

会议期间正处于季节交替之际,易受凉发生感冒、腹泻等疾病。如果有呕吐、腹泻、发烧等症状,请及时通知工作人员。

第六届衰老与肿瘤国	第六届衰老与肿瘤国际学术会议:靶向衰老与肿瘤的共同驱动因子			
日期	12月13日(星期五)	12月14日(星期六)		
海口天气	17-23℃ -	18-22℃		

### 二、推荐酒店

酒店	地址	预订电话	
全季酒店(海口东站店)	海南省海口市龙华区学院路22号金盘名邸2号楼	有省海口市龙华区学院路22号金盘名邸2号楼 0898-3635 6688 (打通转播0)	
海口S-INN栖酒店	海南省海口市龙华区城西路1号	13707582115(刘经理)	

本次会议不收取注册费, 机票酒店费用需自理

### 三、安全须知

- 1.会场安全
- (1)请首先熟悉会场安全出口和疏散通道。
- (2)与会人员众多,进出会场时注意安全,互相谦让,有序出入,避免发生拥挤、推搡、踩踏等事故。
- (3)正确使用会场电器等设施,若需使用临时电源线路或大功率电器,请与工作人员联系。
- (4)如遇突发情况,请保持冷静,立刻联系现场工作人员,并听从现场工作人员的指挥,做好安全疏散。
- 2.消防安全
- (1)请勿在会场及其他禁烟区吸烟;
- (2)请勿将易燃易爆物品带入会场。
- 3.用电安全

」 当您需要连接临时电源线路或使用大功率用电设备时,请与工作人员联系。





























相关事宜	联系人	联系电话
	王雪娇	17589115761
总联系人	符国侦	13078991177
	韩岱芸	18217991869
会场信息支持	易雳	18889770216
会议注册、餐饮	李锦佳	18217881515
赞助商、研究生分论坛	田爱鑫	18589667968
会务组	邝 敏	13976988985
本力组	吴彩璃	13876983799











# **特别鸣谢**















































